Actively Recruiting
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
Led by The University of Hong Kong · Updated on 2026-05-04
372
Participants Needed
3
Research Sites
249 weeks
Total Duration
On this page
Sponsors
T
The University of Hong Kong
Lead Sponsor
R
Research Grants Council, Hong Kong
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery. Recruited patients will be randomized in a 2:1 ratio to receive single subcutaneous dose of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RAs) 1 to 14 days prior to surgery or receive routine care. Dulaglutide (Trulicity; Eli Lilly, USA) is chosen as GLP-1 Receptor Agonists investigational drug for this study. Apart from peri-operative routine care, all recruited subjects will undergo physical, respiratory and cardiac assessments including electrocardiography and blood check including cardiac enzymes. Myocardial injury, cardiovascular outcomes and safety will be assessed and evaluated for efficacy and safety of this prophylactic measurement for the reduction of myocardial injury after non-cardiac surgery.
CONDITIONS
Official Title
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years
- Planned elective intermediate to high risk non-cardiac surgery
- Anticipated to remain hospitalized for at least one night after surgery
- Voluntarily agrees to participate by providing written informed consent
You will not qualify if you...
- History of symptomatic hypoglycemia within 1 month of recruitment
- History of pancreatitis
- Diabetic retinopathy
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Acute coronary syndrome, decompensated heart failure, cardiogenic shock, or myocarditis within 1 month of recruitment
- Stroke or transient ischemic attack within 1 month of recruitment
- Known severe liver disease (Child-Pugh B or C)
- Stage 5 chronic kidney disease (eGFR by MDRD equation < 15 mL/min)
- Recent use of GLP-1 RA within 1 month of recruitment
- Known allergy or hypersensitivity to GLP-1 RA
- Women of childbearing age who are not taking effective contraception, or who are pregnant or breast-feeding
- Use of Dipeptidyl peptidase-4 inhibitor(DPP4i)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Duchess of Kent Children's Hospital at Sandy Bay
Hong Kong, Hong Kong SAR, China
Not Yet Recruiting
2
Queen Mary Hospital
Hong Kong, Hong Kong SAR, China
Actively Recruiting
3
Tung Wah Hospital
Hong Kong, Hong Kong SAR, China
Actively Recruiting
Research Team
C
Chun Ka Wong, Clinical Assistant Professor
CONTACT
L
Lily Hung, Master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here